A bipartisan group of U.S. lawmakers has reportedly launched national security investigations into Merck & Co.
Inc.
(NYSE:MRK) and AbbVie Inc.
(NYSE:ABBV) over concerns that clinical trials conducted in China may have exposed sensitive U.S. biotechnology research to ethical and security risks.
The lawmakers are seeking details about the companies' clinical trial operations, data protection measures and due diligence practices at research sites across China, including facilities in Xinjiang and military-affiliated hospitals.
